Oct 29 (Reuters) - Bausch Health Companies Inc BHC.TO :
* SALIX AND ALFASIGMA WILL INITIATE LATE-STAGE PROGRAM TO STUDY RIFAXIMIN IN PATIENTS WITH POSTOPERATIVE CROHN'S DISEASE
* SALIX PHARMACEUTICALS SAYS ENTERED AMENDMENT TO EXISTING LICENSE AGREEMENT WITH ALFASIGMA S.P.A.
* SALIX PHARMACEUTICALS - CO, ALFASIGMA AGREED TO RESOLVE OUTSTANDING ARBITRATION REGARDING ANOTHER DEVELOPMENT PROJECT FOR FORMULATION OF RIFAXIMIN